37 results
Thumbnail

D1.242 - Early-Life Dietary Diversity and the Risk of Atopic Dermatitis: A Nationwide Population-Based Cohort Study

Thumbnail

D1.244 - Clinical heterogeneity of pediatric atopic dermatitis: latent class analysis

Thumbnail

D1.241 - Clinical and Immunological Phenotypes of Alopecia Areata in Children with Atopic Dermatitis

Thumbnail

D1.236 - The role of tissue resident memory cells in immunodermatological disorders: A Systematic Review

Thumbnail

D1.237 - Mental Health and Neurodevelopmental Comorbidities in Pediatric Atopic Dermatitis: A Retrospective Study and Literature-Based Perspective

Thumbnail

D1.238 - Natural history of early onset atopic dermatitis and risk factors for persistency using Korean National Health Service data

Thumbnail

D1.239 - Are Maternal Epidermal Lipid Profiles Associated with Atopic Dermatitis Development in Early Childhood?

Thumbnail

D1.240 - ATH-409, a selective and covalent ITK inhibitor, protects against atopic dermatitis in preclinical models

Thumbnail

D1.245 - The role of advanced glycation end products as facilitating factors in the pathogenesis of atopic dermatitis in pediatric patients

Thumbnail

D1.246 - Characterization of Unmet Need for Targeted Precision Medication in Atopic Dermatitis Due to Inadequate Response or Adverse Reactions to Dupilumab

Thumbnail

D1.247 - Changes in the sensitization profile in allergic contact dermatitis: comparison between two populations separated by 10 years in a secondary hospital in northern Portugal

Thumbnail

D1.248 - Intersection of Autoimmune Mechanisms: Coexistence of Celiac Disease and Chronic Urticaria

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to